Brian Andrich La Valle Pollo

Dr. Brian Andrich La Valle Pollo

College of Medicine, University of the Philippines Manila, Manila, Philippines
orcid
https://sites.google.com/view/brian-pollo/

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2025 in Case Reports in Clinical Radiology
Verified
Journal Article
Open access
TBTerence Aaron Lim Burgo
Terence Aaron Lim Burgo
Brian Andrich La Valle PolloBrian Andrich La Valle Pollo
Brian Andrich La Valle Pollo
Ohdo syndrome is a rare congenital disorder caused by pathogenic KAT6B variants, with fewer than 30 cases reported globally. We present the first genetically confirmed case in the Philippines: A 16-year-old female with intellectual disability, blepharophimosis, and other craniofacial features. Skeletal survey revealed micrognathia, scoliosis, negative ulnar variance, and digital abnormalities. This case highlights the diagnostic utility of skeletal surveys in documenting phenotypic features, guiding referrals, and supporting clinical recognition of KAT6B-related syndromes such as the Say–Barber–Biesecker–Young–Simpson variant.

28 July 2025 in Research Square
Verified
Preprint
Open access
PDF file
TBTerence Aaron Lim Burgo
Terence Aaron Lim Burgo
Brian Andrich La Valle PolloBrian Andrich La Valle Pollo
Brian Andrich La Valle Pollo
Ohdo syndrome is a rare congenital disorder caused by pathogenic KAT6B variants, with fewer than 30 cases reported globally. We present the first genetically confirmed case in the Philippines: a 16-year-old female with intellectual disability, blepharophimosis, and other craniofacial features. Skeletal survey revealed micrognathia, scoliosis, negative ulnar variance, and digital abnormalities. This case highlights the diagnostic utility of skeletal surveys in documenting phenotypic features, guiding referrals, and supporting clinical recognition of KAT6B-related syndromes like the SBBYS variant.

2 June 2026 in Thesis Commons
Verified
Preprint
Open access
Brian Andrich La Valle PolloBrian Andrich La Valle Pollo
Brian Andrich La Valle Pollo
Background: Synthetic peptides potentially recapitulate properties of whole proteins such as antibody binding and functional activity, thus enabling medical applications in human diseases, especially outbreak situations. Objective: In this study, we wanted to evaluate whether peptides could be used for diagnostic and therapeutic applications in COVID-19.Methods: Peptides were designed from 15 epitope clusters of 7 SARS-CoV-2 structural and nonstructural proteins. Putative complement-activating peptides were also prepared, against which antipeptide antibody αN116 was raised. Diagnostic accuracy of the developed peptide ELISA was determined using 1,222 samples and 218 controls, while functional activities assessed were (1) complement activation through immune adherence hemagglutination, and (2) coagulation modulation through fibrin clot formation and mixing studies.Results: Polymeric S559 demonstrated 2.18-fold increase in apparent avidity (from K_d^app of 63.76 nM⁻¹ to 29.26 nM⁻¹) and post hoc Youden J sensitivity and specificity of 95.01% and 100%, respectively. N115, containing a conserved motif among coronaviruses, triggered dose-dependent C3b deposition, which was abrogated by αN116 and clinical sera. N155-8A, a tunable anticoagulant peptide mixture, suppressed coagulation reversibly over molar ratios of 1:0.55 to 1:2.2, via coaggregation (predicted binding energy: -4.65 kcal/mol). Procoagulant peptide N389 shortened plasma recalcification time to 8.44 ± 6.04 from 23.74 ± 0.004 (p = 0.0012).Conclusion: Peptide analogs of SARS-CoV-2 proteins demonstrated antibody-binding and functional activity, suggesting potential for further development into diagnostics and therapeutics.Keywords: Synthetic peptides, immunoassay, complement activation, coagulation, SARS-CoV-2

21 June 2026 in bioRxiv
Verified
Preprint
Open access
Brian Andrich La Valle PolloBrian Andrich La Valle Pollo
Brian Andrich La Valle Pollo
RORuby Anne Ong
Ruby Anne Ong
Fresthel Monica M. ClimacosaFresthel Monica M. Climacosa
Fresthel Monica M. Climacosa
SCSalvador Eugenio Caoili
Salvador Eugenio Caoili
Background: Complement-mediated hemolysis assays are essential for assessing immune function and diagnosing complement-related disorders. Conventional human erythrocyte derivatization with 2,4,6-trinitrobenzene sulfonic acid (TNBS) can induce nonspecific hemolysis and optical interference, complicating interpretation. Identifying a more biocompatible electrophile could improve assay specificity and reliability. Methods: A panel of aldehydes was screened for electrophilicity using a nucleophile consumption assay with glycine as a model nucleophile. Glyoxylic acid was selected based on reactivity, solubility, and visual neutrality, then neutralized with sodium bicarbonate to minimize baseline hemolysis. Human erythrocytes were sequentially treated with pancreatin and glyoxylic acid to generate glyoxylic acid-pancreatin-treated erythrocytes (GxPEs). Complement-mediated hemolysis was assessed using normal human serum, heat-inactivated serum, and pathway-specific conditions, with CH50 values calculated for total, alternative, and non-alternative pathways. Results: GxPEs exhibited robust complement-specific hemolysis (maximum 93.56%) with negligible background activity in heat-inactivated serum. CH50 analysis confirmed activation via both alternative (0.9514 uL) and non-alternative (1.963 uL) pathways. Reconstitution experiments with factor B-depleted cryoprecipitate and cryosupernatant fractions demonstrated dependence on small complement components such as C2 and C4. Conclusion: Glyoxylic acid derivatization yields a reproducible, optically quiet, and complement-specific erythrocyte substrate suitable for functional hemolysis assays. This method offers a practical platform for complement diagnostics, research applications, and therapeutic evaluation.

7 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
Brian Andrich La Valle PolloBrian Andrich La Valle Pollo
Brian Andrich La Valle Pollo
Fresthel Monica M. ClimacosaFresthel Monica M. Climacosa
Fresthel Monica M. Climacosa
SCSalvador Eugenio Caoili
Salvador Eugenio Caoili
Background: Uncontrolled bleeding complicates trauma, surgery and many medical conditions. While currently available procoagulant therapies ( e . g ., plasma-derived factors, recombinant proteins, antifibrinolytics) have crucial limitations. Methods: N389 (CQQTVTLLPAADLDDFSC) was synthesized by Fmoc solid-phase chemistry, characterized by HPLC and LC–MS, then tested in normal human pooled plasma in microplate mechanical clot-formation assays using incubated and immediate addition formats. Kinetic parameters (plasma recalcification, PRT; maximum absorbance, A max ) were obtained from absorbance curves fit to four-parameter logistic models. Mixing studies with modified ( i . e ., aged, adsorbed) plasma probed factor dependence. Results: In plasma coagulation assays activated with 25 mM CaCl□, baseline clotting showed a PRT of 23.74 ± 0.27 min and A max of 0.1813 ± 0.0043 ( n = 3), whereas N389 significantly reduced PRT to 8.442 ± 6.0395 min without incubation ( p = 0.0012), further decreased PRT after incubation ( p < 0.0001), increased A max to 0.2523, and retained comparable activity across normal, adsorbed, and aged plasma, in contrast to S1255 which showed a faster but incubation-labile effect with PRT 2.353 ± 1.3685 min ( p = 0.0007) and marked attenuation in factor-depleted and aged plasma. Mixing studies showed N389 activity persisted across normal, aged and adsorbed plasma, consistent with a mechanism that does not require intact plasma coagulation factor profiles (specifically factors II, V, VIII, VII, IX, X). Discussion: Collectively with prior evidence on anionic surfaces, Ca 2 □-binding Gla domains, and peptide-modulated fibrin polymerization, these results support a model in which N389 functions as a stable, charge-based scaffold that coordinates divalent cations and/or directly nucleates fibrin(ogen), while highlighting limitations of bulk clotting assays and the need for targeted thrombin generation, binding, aggregation, and contact-activation studies. Conclusions: The aspartate-rich peptide N389 is a sustained, factor-independent procoagulant at least in vitro . N389 thus merits further mechanistic and translational evaluation as a synthetic hemostatic agent.

25 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
TBTerence Aaron Burgo
Terence Aaron Burgo
Brian Andrich La Valle PolloBrian Andrich La Valle Pollo
Brian Andrich La Valle Pollo
Ohdo syndrome is a rare congenital disorder caused by pathogenic KAT6B variants, with fewer than 30 cases reported globally. We present the first genetically confirmed case in the Philippines: a 16-year-old female with intellectual disability, blepharophimosis, and other craniofacial features. Skeletal survey revealed micrognathia, scoliosis, negative ulnar variance, and digital abnormalities. This case highlights the diagnostic utility of skeletal surveys in documenting phenotypic features, guiding referrals, and supporting clinical recognition of KAT6B-related syndromes like the SBBYS variant.